These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 19773288

  • 1. Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis.
    Baldwin HM, Ito-Ihara T, Isaacs JD, Hilkens CM.
    Ann Rheum Dis; 2010 Jun; 69(6):1200-7. PubMed ID: 19773288
    [Abstract] [Full Text] [Related]

  • 2. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
    De Rycke L, Vandooren B, Kruithof E, De Keyser F, Veys EM, Baeten D.
    Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
    [Abstract] [Full Text] [Related]

  • 3. High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity.
    Tokayer A, Carsons SE, Chokshi B, Santiago-Schwarz F.
    J Rheumatol; 2002 Mar; 29(3):454-61. PubMed ID: 11908556
    [Abstract] [Full Text] [Related]

  • 4. Cytokine production from stimulated whole blood cultures in rheumatoid arthritis patients treated with various TNF blocking agents.
    Popa C, Barrera P, Joosten LA, van Riel PL, Kullberg BJ, van der Meer JW, Netea MG.
    Eur Cytokine Netw; 2009 Jun; 20(2):88-93. PubMed ID: 19541595
    [Abstract] [Full Text] [Related]

  • 5. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS.
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [Abstract] [Full Text] [Related]

  • 6. Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis.
    van Roon JA, Hartgring SA, Wenting-van Wijk M, Jacobs KM, Tak PP, Bijlsma JW, Lafeber FP.
    Ann Rheum Dis; 2007 May; 66(5):664-9. PubMed ID: 17185327
    [Abstract] [Full Text] [Related]

  • 7. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S, Ferraccioli G, Ferri C, Galeazzi M, Lapadula G, Cerinic MM, Montecucco C, Triolo G, Trotta F, Valentini G.
    Reumatismo; 2009 May; 61 Suppl 1():1-23. PubMed ID: 19999184
    [Abstract] [Full Text] [Related]

  • 8. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS, Koldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2008 Feb 15; 59(2):234-40. PubMed ID: 18240258
    [Abstract] [Full Text] [Related]

  • 9. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M, Wirthmüller U, Möller B, Villiger PM.
    Rheumatology (Oxford); 2007 Jan 15; 46(1):93-6. PubMed ID: 16720636
    [Abstract] [Full Text] [Related]

  • 10. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay.
    Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL.
    Ann Rheum Dis; 2012 Feb 15; 71(2):231-7. PubMed ID: 22021896
    [Abstract] [Full Text] [Related]

  • 11. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression.
    Netea MG, Radstake T, Joosten LA, van der Meer JW, Barrera P, Kullberg BJ.
    Arthritis Rheum; 2003 Jul 15; 48(7):1853-7. PubMed ID: 12847679
    [Abstract] [Full Text] [Related]

  • 12. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis.
    Van Doornum S, McColl G, Wicks IP.
    Rheumatology (Oxford); 2005 Nov 15; 44(11):1428-32. PubMed ID: 16076882
    [Abstract] [Full Text] [Related]

  • 13. Flow cytometric analysis of phospho-p38 mitogen-activated kinase (MAPK): p38 MAPK does not mediate the effect of adalimumab on peripheral T cell cytokine production in rheumatoid arthritis.
    Aerts NE, Ebo DG, Bridts CH, Stevens WJ, De Clerck LS.
    Cytokine; 2009 Sep 15; 47(3):178-84. PubMed ID: 19616965
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of TNF alpha during maturation of dendritic cells results in the development of semi-mature cells: a potential mechanism for the beneficial effects of TNF alpha blockade in rheumatoid arthritis.
    van Lieshout AW, Barrera P, Smeets RL, Pesman GJ, van Riel PL, van den Berg WB, Radstake TR.
    Ann Rheum Dis; 2005 Mar 15; 64(3):408-14. PubMed ID: 15256380
    [Abstract] [Full Text] [Related]

  • 15. Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis.
    Jongbloed SL, Lebre MC, Fraser AR, Gracie JA, Sturrock RD, Tak PP, McInnes IB.
    Arthritis Res Ther; 2006 Mar 15; 8(1):R15. PubMed ID: 16507115
    [Abstract] [Full Text] [Related]

  • 16. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
    Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, Klareskog L, Ulfgren AK.
    Arthritis Rheum; 2005 Jan 15; 52(1):61-72. PubMed ID: 15641091
    [Abstract] [Full Text] [Related]

  • 17. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity.
    Salemi S, Picchianti-Diamanti A, Germano V, Donatelli I, Di Martino A, Facchini M, Nisini R, Biselli R, Ferlito C, Podestà E, Cappella A, Milanetti F, Rossi F, Amodeo R, Tabacco F, Di Rosa R, Laganà B, D Amelio R.
    Clin Immunol; 2010 Feb 15; 134(2):113-20. PubMed ID: 19846344
    [Abstract] [Full Text] [Related]

  • 18. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C, Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.
    Arthritis Rheum; 2007 May 15; 56(5):1417-23. PubMed ID: 17469098
    [Abstract] [Full Text] [Related]

  • 19. TNF blockade requires 1,25(OH)2D3 to control human Th17-mediated synovial inflammation.
    van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Cornelissen F, van Leeuwen JP, Hazes JM, Dolhain RJ, Bakx PA, Colin EM, Lubberts E.
    Ann Rheum Dis; 2012 Apr 15; 71(4):606-12. PubMed ID: 22219138
    [Abstract] [Full Text] [Related]

  • 20. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis.
    Toubi E, Kessel A, Slobodin G, Boulman N, Pavlotzky E, Zisman D, Rozenbaum M, Rosner I.
    Ann Rheum Dis; 2007 Jun 15; 66(6):818-20. PubMed ID: 17148544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.